查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1847939

嗜中性白血球低下症治療市場按治療類型、治療層級、給藥途徑、分銷管道、最終用戶、患者年齡層和嚴重程度分類 - 全球預測 2025-2032

Neutropenia Treatment Market by Treatment Type, Therapy Class, Route Of Administration, Distribution Channel, End User, Patient Age Group, Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年嗜中性白血球低下症治療市場將成長至 225.4 億美元，複合年成長率為 5.14%。

主要市場統計數據
基準年2024年 150.8億美元
預計2025年 158.5億美元
預測年份：2032年 225.4億美元
複合年成長率（%） 5.14%

簡明說明醫療機構和相關人員在臨床、操作和商業性對嗜中性白血球低下症減少症治療方案的影響

嗜中性白血球低下症是腫瘤科、血液科以及許多住院和門診病人環境中的核心臨床挑戰，需要採取既能降低感染風險又能及時繼續進行疾病修正治療的治療手段。過去十年，生長因子生物學和藥物傳輸技術的進步顯著改變了臨床實踐，但在藥物取得、處方模式以及支持安全居家用藥的基礎設施方面仍然存在顯著差異。本執行摘要綜合了當代臨床實踐、輸送機制和策略性產業變革，旨在為相關人員提供資訊，幫助他們應對複雜的治療和商業生態系統。

決策者所處的環境涵蓋多種醫療保健環境，從醫院、診所到家庭輸液服務，安全通訊協定、報銷政策和病人偏好的相互作用決定了可觀察到的用藥情況。臨床醫師擴大權衡短效與長效顆粒細胞增生因子的益處，同時也要考慮給藥的便利性、不利事件概況以及輸液單元的運作負擔等因素。此外，圍繞基於價值的採購和生物相似藥採用的對話正在加劇，採購團隊、付款人和供應商正在重新調整顆粒細胞增生因子，以使臨床結果與成本和供應可靠性保持一致。本引言透過確定未滿足的需求、現實世界的營運限制和策略槓桿來建構以下章節，這些因素決定了商業、臨床和政策領域的近期決策。

生物相似藥、長效製劑、數位監控和基於價值的採購如何融合，重新定義嗜中性白血球低下症治療途徑

監管、技術和商業性力量正在改變嗜中性白血球低下症的治療格局，這些力量正在重塑治療方法的開發、交付和採購方式。一個顯著的轉變是生物相似藥和可互換生技藥品的主流化，這正在改變採購動態，並鼓勵更強力的主導的管理模式。同時，長效製劑和最佳化的給藥策略正在降低給藥頻率，為更安全、更可擴展的家庭給藥方案鋪平道路，並改變醫院藥房和居家照護提供者所需的服務組合。

新的數位化工具和遠端監控平台正在實現對嗜中性白血球低下患者的更密切監測，使臨床醫生能夠更早識別感染風險並更有效地進行分診。數位化的成熟度與供應鏈創新和對本地製造的投資相輔相成，旨在減少中斷並支持即時交付模式。同時，基於價值的合約和與結果掛鉤的採購在大型綜合醫療保健網路中日益盛行，這要求製造商不僅要證明臨床等效性，還要證明住院和感染相關成本的顯著降低。這些趨勢迫使相關人員重新思考產品定位、證據產生策略和跨職能協作，以獲取臨床和經濟價值。

評估 2025 年美國關稅計劃變化對嗜中性白血球低下症藥物供應鏈、採購行為和籌資策略的多方面影響

近期貿易政策發展和已宣布的2025年關稅調整對用於嗜中性白血球低下症減少症治療的生物製藥的治療供應鏈和籌資策略產生了多方面的影響。更高的進口關稅可能會增加成品和關鍵原料的到岸成本，迫使製造商和經銷商重新評估籌資策略和庫存緩衝。為此，企業可能會加快對本地製造的投資或調整其供應商組合，以保護利潤率，並維持對依賴Filgrastim和Pegfilgrastim產品可預測交付的醫院、門診病人中心和居家照護機構的交付連續性。

同時，購買者和付款人正在透過加強處方集管理和改進競標流程來應對不斷上升的採購成本，以強調治療總成本而不僅僅是單位成本。這導致人們對生物學名藥替代的興趣增加，並可能刺激製造商和付款人之間的風險共用契約機制，例如基於結果的基本契約，這與減少與嗜中性白血球低下症相關的住院治療有關。新的關稅制度也改變了監管和合規考慮，增加了供應鏈團隊的行政負擔，他們必須記錄來源、協調關稅分類並確保低溫運輸物流的連續性。最終，關稅變化的累積效應是加速向本地化、供應策略多樣化以及付款人、醫療保健提供者和製造商之間更密切合作的結構性轉變，以在限制性貿易環境中保持可及性和可負擔性。

一個全面的細分框架，將治療方式、治療層級、給藥途徑、分銷管道和患者群體與可操作的策略重點聯繫起來

細緻的細分視角揭示了嗜中性白血球低下症治療的臨床需求、商業策略和服務產品的交匯點。治療類型分為非格司亭、Filgrastim司亭和聚乙二醇Pegfilgrastim，其中Filgrastim進一步細分為300微克、480微克和600微克劑量，來格司亭細分為3毫克和5毫克劑量，Pegfilgrastim通常為6毫克劑量。這些差異影響處方模式、管瓶和注射器規格以及低溫運輸合作夥伴的冷鏈物流。治療層級將生物相似藥與原廠藥區分開來，這一區別決定了證據生成要求、價格談判和上市策略。

給藥途徑在操作和臨床上都很重要，因為靜脈給藥或皮下給藥決定了治療的地點和藥房的組織方式。分銷管道細分包括醫院藥房、線上藥房和零售藥房，其中醫院藥房進一步分為住院藥房和門診病人居家照護和醫院，醫院本身分為私立和公立，從而導致機構購買行為和處方集多樣化。患者年齡細分為成人、老年和兒科組，突顯了劑量、安全監測和依從性支持需求的差異。最後，基於嚴重程度的細分將病例分為輕度、中度或嗜中性白血球低下症減少症，確定臨床緊急程度、預防性或反應性使用集落刺激因子，以及所需支持服務的強度。這種組合細分框架允許相關人員根據每個患者群體和護理環境的特定需求量身定做臨床證據、商業性策略和營運投資。

亞太地區、歐洲、中東和非洲的區域市場動態和基礎設施差異決定了嗜中性白血球低下症藥物的取得、採購和交付策略

區域動態極大地影響嗜中性白血球低下症藥物的可及性、監管預期和商業性執行，每個宏觀區域都呈現出獨特的機會和限制因素。在美洲，相關人員面臨影響生物相似藥和長效藥物吸收的異質支付系統，而先進的分銷網路和強大的居家醫療基礎設施則支持門診用藥的擴展。歐洲、中東和非洲地區以其監管多樣性而聞名。雖然歐洲成熟市場通常擁有成熟的生物相似藥途徑和集中採購流程，但中東和非洲部分地區的基礎設施多樣化，並且在低溫運輸配送和臨床醫生培訓方面受到不同的限制。亞太地區以其快速擴張的生產能力、充滿活力的生物相似藥開發生態系統和不斷發展的國內製造業而著稱，這些因素可以提高當地的供應彈性，但也帶來了競爭性的價格壓力。

在全部區域，醫院所有權模式、門診醫療滲透率以及家庭輸液服務成熟度的差異決定了產品創新和服務模式的吸引力。對於跨國製造商和經銷商，這些區域差異需要差異化的監管策略、滿足區域醫療技術評估 (HTA) 期望的有針對性的證據包，以及反映付款方成熟度和採購規範的客製化合約方式。此外，每個地區的物流和關稅環境都會影響公司的採購決策，因此，製造和倉儲的地理多元化是全球市場保持穩定供應和滿足不斷變化的需求狀況的重要考慮因素。

原廠藥製造商、生物相似藥參與企業和服務供應商之間的企業策略和競爭行動決定了嗜中性白血球低下症治療的招募、簽約和供應彈性

中性粒細胞減少症治療領域的競爭態勢由眾多生物製藥公司、成熟的學名藥和生物類似藥開發商，以及支持低溫運輸和家庭輸液服務的專業契約製造製造商和服務供應商嗜中性白血球低下症​​。原廠公司保留臨床品牌股權和深厚的臨床試驗歷史，以支持付款人談判和醫院處方集的納入；而生物類似藥參與企業則利用生產規模和經濟高效的途徑來贏得競標並擴大可及性。一些公司也採取了類似的策略，力求實現差異化，例如透過降低劑量、開展患者援助項目以及開展基於價值的合約試點項目，以降低嗜中性白血球低下症減少症的住院率。

一些製造商正在優先考慮綜合支援服務，從皮下自主給藥的護理師培訓到數位依從性工具，以減輕輸液中心的工作量，並使門診給藥更加可行。受託製造廠商和區域灌裝合作夥伴對於維持供應的連續性至關重要，尤其是在關稅引發的資源轉移背景下。總而言之，這種競爭格局表明，臨床證據、服務交付、供應彈性以及價格對於確保醫院、診所和家庭護理機構的長期採用至關重要。

製造商、付款人和醫療保健提供者需要採取切實可行的策略措施，以協調嗜中性白血球低下症藥物證據、供應彈性和以患者為中心的服務模式

產業領導者應優先採取一系列行動，協調臨床證據產生、供應鏈韌性和付款人參與，以確保藥品的永續可及性和商業性可行性。首先，製造商應投資於實用性試驗和真實世界證據，這些試驗和證據不僅能證明臨床等效性，還能降低住院率和資源利用率。其次，企業應實現製造地多元化，並與當地灌裝合作夥伴制定應急計劃，以降低關稅變化和物流瓶頸帶來的營運風險，並確保醫院和居家照護機構的配送可靠性。

第三，相關人員必須深化付款人與提供者之間的夥伴關係，強調總醫療成本指標和以病人為中心的結果。協調獎勵使製造商能夠根據嗜中性白血球低下症減少併發症的減少情況協商風險回報共用協議。第四，擴大患者支援服務和培訓計劃，以實現安全的皮下或家庭給藥，這將減輕系統負擔並改善患者體驗，特別是在成人和老年人群中。第五，商業團隊應根據管道和最終用戶自訂打入市場策略，針對住院藥房、門診病人診所、零售連鎖店和線上藥局採取不同的策略。最後，整合數位監控和遠端醫療可以提高藥物依從性，實現更早的感染檢測，並提供可操作的數據，從而提高特定治療方法的臨床和經濟價值。這些綜合行動為臨床影響和商業性永續性開闢了一條可行的道路。

結合臨床醫師訪談、現場檢驗和二手文獻綜合的嚴格混合方法研究途徑，產生了可行的見解和實際局限性

本執行摘要所依據的研究整合了主要研究和次要研究，以確保獲得可靠、經三角檢驗的發現，從而反映當前的臨床實踐和商業性動態。主要研究包括對住院和門診臨床醫生、醫院系統內的供應鏈負責人以及參與生技藥品採購和分銷的公司高管進行的結構化訪談。次要研究包括同行評審的臨床文獻、監管指南文件以及藥房和居家醫療模式的營運分析，這些研究被整合在一起，以將訪談見解與實際情境聯繫起來，並檢驗觀察到的趨勢。

透過迭代交叉驗證對資料進行三角檢驗，將訪談中的定性見解與已發表的臨床研究結果和政策報告進行比較，以確定一致的主題並確定需要進一步進行初步研究的領域。品質保證措施包括由臨床顧問和供應鏈專家進行專家檢驗，以確保營運敘述和策略影響的準確性和可操作性。雖然本調查方法注重深度和實際相關性，但具體的司法管轄細節和保密合約條款超出了本分析的範圍，需要進行有針對性的初步研究才能完全揭示。儘管如此，這種方法為尋求將臨床策略與商業性執行相結合的決策者提供了嚴謹的基礎。

關於綜合證據、供應彈性和付款人協調如何決定未來獲得和提供嗜中性白血球低下症治療的綜合結論。

摘要，嗜中性白血球低下症治療領域正經歷著巨大的變革，其驅動力包括生物學名藥的普及、長效療法的可及性、區域性生產轉移以及支付方預期的不斷變化。這些因素將影響治療的提供地點、產品的採購方式，以及確保並維持醫院、診所、居家醫療和藥房管道採用該藥物所需的證據。因此，臨床團隊和商業領袖必須採取整合策略，以解決證據產生、供應鏈穩健性和差異化市場進入，從而在日益以價值為導向的採購環境中取得成功。

展望未來，積極主動地將臨床結果與營運可行性和付款方優先事項結合的相關人員，將最有能力提供以患者為中心的醫療服務，同時保持商業性可行性。持續監測關稅和貿易發展，並投資於本地能力建設和數位化患者管理，對於管理風險和充分發揮治療創新的潛力至關重要。這項結論強調，必須採取循證協作行動，以實現更安全的病人歷程和更永續的服務提供模式。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • Pegfilgrastim體內注射器上市，以提高病患依從性
  • Filgrastim生物相似藥的日益普及推動了成本競爭力
  • 門診病人口服顆粒細胞增生因子類似物的開發
  • 整合藥物基因體學制定嗜中性白血球低下症預防策略
  • 專注於 CXCR4 拮抗劑的研發管線，旨在促進移植患者的嗜中性白血球恢復
  • 擴展數位監測工具以追蹤嗜中性白血球計數和治療依從性
  • 加強支持性治療的報銷政策將促進 G-CSF 療法的採用
  • 化療嗜中性白血球低下症發生率上升推動新興市場成長

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

嗜中性白血球低下症治療市場（依治療類型）

  • Filgrastim
    • 300微克
    • 480微克
    • 600微克
  • 來諾格司亭
    • 3mg
    • 5mg
  • Pegfilgrastim
    • 6mg

嗜中性白血球低下症市場治療類別

  • 生物相似藥
  • 創辦人

嗜中性白血球低下症治療市場（依給藥途徑）

  • 靜脈注射
  • 皮下注射

嗜中性白血球低下症治療市場（按分銷管道）

  • 醫院藥房
    • 住院藥房
    • 門診藥房
  • 網路藥局
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

嗜中性白血球低下症治療市場（依最終使用者）

  • 門診治療中心
  • 診所
  • 居家護理
  • 醫院
    • 私人的
    • 公共

嗜中性白血球低下症治療市場（依患者年齡層）

  • 成人
  • 老年人
  • 孩子們

嗜中性白血球低下症治療市場（依嚴重程度）

  • 溫和的
  • 緩和
  • 嚴重

嗜中性白血球低下症治療市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

嗜中性白血球低下症治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

嗜中性白血球低下症治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amgen Inc.
    • Sandoz International GmbH
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Coherus BioSciences, Inc.
    • Fresenius Kabi AG
    • Intas Pharmaceuticals Ltd.
    • Biocon Limited
    • Celltrion, Inc.
Product Code: MRR-FB6C9E793876

The Neutropenia Treatment Market is projected to grow by USD 22.54 billion at a CAGR of 5.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.08 billion
Estimated Year [2025] USD 15.85 billion
Forecast Year [2032] USD 22.54 billion
CAGR (%) 5.14%

A concise orientation to the current clinical, operational, and commercial realities shaping neutropenia treatment choices across care settings and stakeholders

Neutropenia remains a central clinical challenge across oncology, hematology, and many inpatient and ambulatory care settings, demanding treatments that reduce infection risk while enabling the timely continuation of disease-modifying therapies. Advances in growth factor biology and drug delivery have reframed clinical practice over the past decade, yet significant variation persists in access, prescribing patterns, and the infrastructure that supports safe at-home administration. This executive summary synthesizes contemporary clinical practice, delivery mechanisms, and strategic industry shifts to inform stakeholders navigating a complex therapeutic and commercial ecosystem.

The context for decision-makers spans multiple care settings, from hospitals and clinics to home infusion services, where the interplay of safety protocols, reimbursement policies, and patient preferences shapes observable uptake. Clinicians increasingly weigh the comparative benefits of short-acting versus long-acting granulocyte-colony stimulating factors alongside considerations such as dosing convenience, adverse event profiles, and the operational burden on infusion units. Moreover, the dialogue around value-based procurement and biosimilar adoption has intensified, with procurement teams, payers, and providers recalibrating formularies to align clinical outcomes with cost and supply reliability. This introduction frames the subsequent sections by establishing the unmet needs, real-world operational constraints, and strategic levers that will define near-term decisions across commercial, clinical, and policy domains.

How biosimilar momentum, long-acting formulations, digital monitoring, and value-based purchasing are converging to redefine neutropenia treatment pathways

The neutropenia treatment landscape is undergoing transformative shifts driven by regulatory, technological, and commercial forces that are reshaping how therapies are developed, delivered, and procured. One prominent shift is the mainstreaming of biosimilars and interchangeable biologics, which have altered procurement dynamics and prompted intensified payer-led stewardship models. Concurrently, long-acting formulations and optimized dosing strategies have reduced administration frequency and opened the door to safer, more scalable home administration programs, changing the service mix required from hospital pharmacies and home care providers alike.

Emerging digital tools and remote monitoring platforms are enabling closer surveillance of neutropenic patients, allowing clinicians to identify infection risk earlier and triage care more effectively. This digital maturation is complemented by supply-chain innovations and regional manufacturing investments that seek to mitigate disruptions and support just-in-time delivery models. In parallel, value-based contracting and outcome-linked purchasing are gaining traction among larger integrated delivery networks, encouraging manufacturers to demonstrate not just clinical equivalence but measurable reductions in hospitalization and infection-related costs. These converging trends compel stakeholders to rethink product positioning, evidence generation strategies, and cross-functional collaboration to capture both clinical and economic value.

Assessing the multifaceted effects of the United States tariff changes slated for 2025 on supply chains, procurement behaviors, and sourcing strategies for neutropenia therapies

Recent trade policy developments and tariff adjustments announced for 2025 have a multifaceted impact on therapeutic supply chains and procurement strategies for biologic agents used in neutropenia management. Increased import tariffs can raise landed costs for finished products and critical raw materials, prompting manufacturers and distributors to reassess sourcing strategies and inventory buffers. In response, firms may accelerate regional manufacturing investments or alter supplier portfolios to protect margins and maintain supply continuity for hospitals, outpatient centers, and home care providers that depend on predictable deliveries of filgrastim, lenograstim, and pegfilgrastim products.

At the same time, purchasers and payers respond to higher acquisition costs by tightening formulary controls and reinforcing tender processes that emphasize total cost of care rather than unit price alone. This may amplify interest in biosimilar alternatives and stimulate contractual mechanisms that share risk between manufacturers and payers, such as outcomes-based agreements tied to reductions in febrile neutropenia-related admissions. Regulatory and compliance considerations also evolve under new tariff regimes, increasing the administrative burden on supply chain teams that must document provenance, harmonize customs classifications, and ensure continuity of cold chain logistics. Ultimately, the cumulative effect of tariff changes is to accelerate structural shifts toward localized production, diversified supply strategies, and closer payer-provider-manufacturer collaboration to preserve access and affordability in a constrained trade environment.

A comprehensive segmentation framework that links treatment modalities, therapy classes, administration routes, distribution channels, and patient cohorts to actionable strategic priorities

A nuanced segmentation lens reveals where clinical demand, commercial strategy, and service delivery intersect for neutropenia treatments. Treatment type divides into filgrastim, lenograstim, and pegfilgrastim, with filgrastim further differentiated into dosages of 300 mcg, 480 mcg, and 600 mcg, lenograstim split across 3 mg and 5 mg strengths, and pegfilgrastim typically represented by 6 mg dosing; these distinctions influence prescribing patterns, vial and syringe formats, and cold-chain logistics for distribution partners. The therapy class dimension separates biosimilar offerings from originator molecules, a distinction that drives evidence-generation requirements, pricing negotiations, and market access tactics.

Route of administration matters operationally and clinically, with intravenous injection and subcutaneous injection pathways shaping where care is delivered and how pharmacy services organize. Distribution channel segmentation includes hospital pharmacy, online pharmacy, and retail pharmacy, with hospital pharmacy further categorized into inpatient and outpatient pharmacy units, and retail pharmacy differentiated between chain and independent operators; these channels each present unique inventory management, reimbursement, and point-of-care education challenges. End user segmentation spans ambulatory care centers, clinics, home care, and hospitals, while hospitals themselves are segmented into private and public institutions, creating diverse institutional purchasing behaviors and formularies. Patient age group stratification into adult, geriatric, and pediatric cohorts highlights differential dosing, safety monitoring, and adherence support needs. Finally, severity-based segmentation classifies cases as mild, moderate, or severe neutropenia, which determines clinical urgency, prophylactic versus reactive use of colony-stimulating factors, and the intensity of supportive services required. This composite segmentation framework enables stakeholders to tailor clinical evidence, commercial tactics, and operational investments to the specific demands of each patient cohort and care setting.

Regional market dynamics and infrastructure variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access, procurement, and delivery strategies for neutropenia therapies

Regional dynamics materially shape access, regulatory expectations, and commercial execution for neutropenia therapies, with each macro-region presenting distinct opportunities and constraints. In the Americas, stakeholders contend with heterogeneous payer systems that influence uptake of biosimilars and long-acting agents, while advanced distribution networks and strong home care infrastructure support expanded ambulatory administration. Europe, Middle East & Africa displays considerable regulatory diversity; established European markets often have mature biosimilar pathways and centralized procurement processes, whereas parts of the Middle East and Africa exhibit variable infrastructure and differing constraints on cold-chain distribution and clinician training. The Asia-Pacific region is marked by rapid capacity expansion, an active biosimilar development ecosystem, and growing domestic manufacturing that can improve local supply resilience but also introduces competitive pricing pressures.

Across these regions, differences in hospital ownership models, outpatient care penetration, and the maturity of home infusion services shape where product innovation and service models will gain traction. For multinational manufacturers and distributors, these regional contrasts require differentiated regulatory strategies, targeted evidence packages to meet local HTA expectations, and bespoke contracting approaches that reflect payer sophistication and procurement norms. Moreover, regional logistics and tariff environments interact with corporate sourcing decisions, so geographic diversification of manufacturing and warehousing is an essential consideration for sustaining consistent supply and meeting variable demand profiles across global markets.

Corporate strategies and competitive behaviors among originator manufacturers, biosimilar entrants, and service providers that determine adoption, contracting, and supply resilience in neutropenia care

Competitive dynamics in neutropenia treatment are shaped by a mix of originator biologic manufacturers, established generics and biosimilar developers, and specialized contract manufacturers and service providers that support cold chain and home infusion services. Originator companies retain clinical brand equity and deep clinical trial histories that support payer negotiations and hospital formulary positioning, while biosimilar entrants leverage manufacturing scale and cost-efficient pathways to win tenders and expand access. Parallel strategies are evident among companies investing to differentiate through reduced dosing regimens, patient support programs, and value-based contracting pilots that emphasize reduced hospitalization rates for febrile neutropenia.

Several manufacturers have prioritized integrated support services-ranging from nurse training for subcutaneous self-administration to digital adherence tools-to lower the operational burden on infusion centers and to make outpatient management more feasible. Contract manufacturing organizations and regional fill-and-finish partners have become critical for maintaining supply continuity, particularly in the context of tariff-induced resourcing shifts. Collectively, these company-level approaches underscore a competitive landscape where clinical evidence, service delivery, and supply resilience are as decisive as price in securing long-term adoption across hospitals, clinics, and home care providers.

Actionable strategic imperatives for manufacturers, payers, and providers to align evidence, supply resilience, and patient-centered service models for neutropenia therapies

Industry leaders should prioritize a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to secure sustainable access and commercial viability. First, manufacturers should invest in pragmatic trials and real-world evidence that demonstrate not only clinical equivalence but also reductions in hospitalizations and resource utilization; this evidence supports value-based contracting and strengthens positioning in tender-driven environments. Second, firms should diversify manufacturing footprints and develop contingency plans with regional fill-and-finish partners to mitigate the operational risk posed by tariff shifts and logistic bottlenecks, thereby protecting delivery reliability for hospitals and home care operators.

Third, stakeholders must deepen payer and provider partnerships that focus on total cost of care metrics and patient-centered outcomes; by aligning incentives, manufacturers can negotiate contracts that share risk and reward based on demonstrable reductions in febrile neutropenia complications. Fourth, expanding patient support services and training programs to enable safe subcutaneous or at-home administration will reduce system burden and improve patient experience, particularly for adult and geriatric cohorts. Fifth, commercial teams should tailor market access strategies by channel and end user, differentiating approaches for inpatient pharmacy, outpatient clinics, retail chains, and online pharmacies. Finally, embracing digital monitoring and telehealth integrations can strengthen adherence, enable early infection detection, and produce actionable data that reinforce the clinical and economic value of specific treatment regimens. Taken together, these actions create a defensible pathway to both clinical impact and commercial sustainability.

A rigorous mixed-methods research approach combining clinician interviews, operational validation, and secondary literature synthesis to produce actionable insights and practical limitations

The research underpinning this executive summary integrates both primary and secondary inputs to ensure robust, triangulated findings that reflect current clinical practice and commercial dynamics. Primary research included structured interviews with clinicians across inpatient and outpatient settings, supply chain leaders within hospital systems, and commercial executives involved in biologics procurement and distribution. Secondary research comprised peer-reviewed clinical literature, regulatory guidance documents, and operational analyses of pharmacy and home care delivery models, synthesized to contextualize interview insights and to validate observed trends.

Data were triangulated through iterative cross-validation exercises, where qualitative insights from interviews were compared against published clinical outcomes and policy reports to identify consistent themes and to flag areas requiring further primary inquiry. Quality assurance measures included expert review by clinical advisors and supply chain specialists to ensure that operational descriptions and strategic implications were accurate and actionable. Limitations are acknowledged: while the methodology prioritizes depth and practical relevance, certain jurisdictional specifics and confidential contracting terms are beyond the scope of the present analysis and would require targeted primary engagement for full elucidation. Nevertheless, the approach provides a rigorous foundation for decision-makers seeking to align clinical strategy with commercial execution.

Consolidated conclusions on how integrated evidence, supply resilience, and payer alignment will determine the future accessibility and delivery of neutropenia treatments

In summary, the neutropenia treatment environment is navigating a period of substantive change driven by biosimilar adoption, long-acting therapy availability, regional manufacturing shifts, and evolving payer expectations. These forces jointly influence where care is delivered, how products are procured, and what evidence is required to secure and sustain adoption across hospitals, clinics, home care, and pharmacy channels. Clinical teams and commercial leaders must therefore adopt integrated strategies that address evidence generation, supply-chain robustness, and differentiated market access to succeed in increasingly value-oriented procurement environments.

Moving forward, stakeholders who proactively align clinical outcomes with operational feasibility and payer priorities will be best positioned to deliver patient-centered care while preserving commercial viability. Continued monitoring of tariff and trade developments, coupled with investments in regional capacity and digital patient management, will be central to managing risk and realizing the full potential of therapeutic innovations. This conclusion underscores the imperative for collaborative, evidence-driven actions that translate into safer patient journeys and more sustainable service delivery models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market entry of pegfilgrastim on-body injector devices improving patient adherence
  • 5.2. Rising adoption of biosimilar filgrastim products driving cost competitive dynamics
  • 5.3. Development of oral granulocyte colony-stimulating factor analogs for outpatient use
  • 5.4. Integration of pharmacogenomics for personalized neutropenia prophylaxis dosing strategies
  • 5.5. Pipeline focus on CXCR4 antagonists for accelerated neutrophil recovery in transplant patients
  • 5.6. Expansion of digital monitoring tools to track neutrophil counts and treatment compliance
  • 5.7. Increased supportive care reimbursement policies boosting adoption of G-CSF therapies
  • 5.8. Growth of emerging markets with rising chemotherapy-induced neutropenia incidence rates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neutropenia Treatment Market, by Treatment Type

  • 8.1. Filgrastim
    • 8.1.1. 300 mcg
    • 8.1.2. 480 mcg
    • 8.1.3. 600 mcg
  • 8.2. Lenograstim
    • 8.2.1. 3 mg
    • 8.2.2. 5 mg
  • 8.3. Pegfilgrastim
    • 8.3.1. 6 mg

9. Neutropenia Treatment Market, by Therapy Class

  • 9.1. Biosimilar
  • 9.2. Originator

10. Neutropenia Treatment Market, by Route Of Administration

  • 10.1. Intravenous Injection
  • 10.2. Subcutaneous Injection

11. Neutropenia Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
    • 11.1.1. Inpatient Pharmacy
    • 11.1.2. Outpatient Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Neutropenia Treatment Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
    • 12.4.1. Private
    • 12.4.2. Public

13. Neutropenia Treatment Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Neutropenia Treatment Market, by Severity

  • 14.1. Mild
  • 14.2. Moderate
  • 14.3. Severe

15. Neutropenia Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Neutropenia Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Neutropenia Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Amgen Inc.
    • 18.3.2. Sandoz International GmbH
    • 18.3.3. Pfizer Inc.
    • 18.3.4. Teva Pharmaceutical Industries Ltd.
    • 18.3.5. Viatris Inc.
    • 18.3.6. Coherus BioSciences, Inc.
    • 18.3.7. Fresenius Kabi AG
    • 18.3.8. Intas Pharmaceuticals Ltd.
    • 18.3.9. Biocon Limited
    • 18.3.10. Celltrion, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NEUTROPENIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. NEUTROPENIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUTROPENIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 300 MCG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 480 MCG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 600 MCG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 3 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 5 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY 6 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ORIGINATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUTROPENIA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA NEUTROPENIA TREATMENT MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY FILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY LENOGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY PEGFILGRASTIM, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA NEUTROPENIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. EU